Why is iron status essential when using ESAs in CKD?

• A. Iron deficiency has no impact on ESA efficacy
• B. Iron deficiency reduces ESA efficacy; iron repletion improves response
• C. Iron supplementation is contraindicated with ESAs
• D. Iron status is not important in CKD anemia management

Answer: (B)

Iron availability is essential when using erythropoiesis-stimulating agents in CKD because ESAs stimulate the bone marrow to make more red blood cells, and that production requires iron to form hemoglobin. If iron stores are low or iron is being sequestered due to inflammation (functional iron deficiency), the new red cells can’t be produced efficiently, so the hemoglobin response to ESAs is limited. Replenishing iron often improves ESA response and helps reach target hemoglobin levels. In CKD, iron deficiency is common from dialysis-related blood loss, reduced intake, and inflammatory changes that increase hepcidin. Therefore, assessing iron status and providing iron as needed is a standard part of ESA therapy. Iron is not contraindicated with ESAs, and iron status is important in CKD anemia management.